ID3 and cancer: In patients with LGG, Thym, DLBC and COAD, we also found at least one subgroup of patients with low ID3 expression and low HR enrichment score, indicating that low ID3 expression in specific subgroups of cancer patients is associated with impaired HR-related pathways.